Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
January 12, 2022 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
- Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 – - Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with...
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
January 10, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 06, 2022 08:02 ET
|
Senti Bio
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (“Senti Bio”), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and...